Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2010 | Research

Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis

Authors: Zhi-Dong Lv, Di Na, Fu-Nan Liu, Zong-Min Du, Zhe Sun, Zhen Li, Xiao-Yang Ma, Zhen-Ning Wang, Hui-Mian Xu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Abstract

Background

Peritoneal dissemination is one of the main causes of death in gastric cancer patients. Transforming growth factor-beta1 (TGF-β1), one of the most potent fibrotic stimuli for mesothelial cells, may play a key role in this processing. The purpose of this study is to elucidate the effects of TGF-β1 on regulation of gastric cancer adhesion to mesothelial cells.

Methods

Peritoneal tissues and peritoneal wash fluid were obtained for hematoxylin and eosin staining or ELISA to measure fibrosis and TGF-β1 levels, respectively. The peritoneal mesothelial cell line, HMrSV5, was used to determine the role of TGF-β1 in regulation of gastric cancer cell adhesion to mesothelial cells and expression of collagen, fibronectin, and Smad 2/3 by using adhesion assay, western blot, and RT-PCR.

Results

The data showed that TGF-β1 treatment was able to induce collagen III and fibronectin expression in the mesothelial cells, which was associated with an increased adhesion ability of gastric cancer cells, but knockdown of minimal sites of cell binding domain of extracellular matrix can partially inhibit these effects.

Conclusion

Peritoneal fibrosis induced by TGF-β1 may provide a favorable environment for the dissemination of gastric cancer.

Available only for authorised users

Paul L, Emad M: Gastric cancer. Br Med Bull. 2008, 85: 87-100. 10.1093/bmb/ldn007.CrossRef

Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24: 2137-2150. 10.1200/JCO.2005.05.2308.CrossRef

Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef

Sugarbaker PH, Yonemura Y: Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: Bestpalliation with a ray of hope for cure. Oncology. 2000, 58: 96-107. 10.1159/000012086.CrossRef

Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-573. 10.1016/S0140-6736(00)49915-0.CrossRef

Chau I, Norman AR, Cunningham D: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004, 22: 2395-2403. 10.1200/JCO.2004.08.154.CrossRef

Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M: Fibrosis in the peritoneum induces by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer. 1996, 77: s1668-s1674.CrossRef

Rieppi M, Vergani V, Gatto C, Zanetta G, Allavena P, Taraboletti G, Giavazzi R: Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer. 1999, 80: 303-307. 10.1002/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.0.CO;2-W.CrossRef

Ahmed N, Riley C, Rice G, Quinn M: Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Met. 2005, 22: 391-402. 10.1007/s10585-005-1262-y.CrossRef

10.

Border WA, Noble NA: Transforming growth factor-beta in tissue fibrosis. N Engl J Med. 1994, 331: 1286-1292. 10.1056/NEJM199411103311907.CrossRef

11.

Margetts PJ, Oh KH, Kolb M: Transforming growth factor-beta: importance in long-term peritoneal membrane changes. Perit Dial Int. 2005, 25: S15-S17.

12.

Hironobu L: Pathogenesis of fibrosis: role of TGF-β and CTGF. Curr Opin Rheumatol. 2002, 14: 681-68. 10.1097/00002281-200211000-00009.CrossRef

13.

Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A: High levels of transforming growth factor-β1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarker Preven. 1995, 4: 549-554.

14.

Kinugasa S, Abe S, Tachibana M: Overexpression of transforming growth factor-β1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology. 1998, 55: 582-587. 10.1159/000011916.CrossRef

15.

Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M: An elevated serum level of transforming growth factor-β1(TGF-β1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000, 20: 4489-4493.

16.

Miyazono K, Suzuki H, Imamura T: Regulation of TGF-β signaling and its roles in progression of tumors. Cancer Sci. 2003, 94: 230-234. 10.1111/j.1349-7006.2003.tb01425.x.CrossRef

17.

Tasuku M, Kosei H, Masakazu Y, Shigehiko N, Tetsuji S, Ikuo S, Michio S: Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Met. 1998, 16: 381-388.

18.

Alkhamesi NA, Ziprin P, Pfistermuller K: ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Met. 2005, 22: 449-459. 10.1007/s10585-005-2893-8.CrossRef

19.

Ksiazek K, Mikula-Pietrasik J, Korybalska K: Senescent Peritoneal Mesothelial Cells Promote Ovarian Cancer Cell Adhesion. Am J Pathol. 2009, 174: 1231-1240. 10.2353/ajpath.2009.080613.CrossRef

20.

Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM: Interactions between cancer cells and the endothelium in metastasis. J Pathol. 2000, 190: 310-329. 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P.CrossRef

21.

Tsuji T, Kawada Y, Kai-Murozono M: Regulation of melanoma cell migration and invasion by laminin-5 and alpha3beta1 integrin (VLA-3). Clin Exp Met. 2002, 19: 127-134. 10.1023/A:1014573204062.CrossRef

22.

Michailova KN: Mesothelial lamellar bodies in norm and experimental conditions. Transmission and scanning electron microscopic observations on the peritoneum, pleura and pericardium. Anat Embryol (Berl). 2004, 208: 301-309.CrossRef

23.

Liu Q, Mao H, Nie J: Transforming growth factor-beta1 induces epithelial-mesenchymal transition by activating the JNK-Smad3 pathway in rat peritoneal mesothelial cells. Peritoneal Dialysis Int. 2008, 28: s88-s95.

24.

Oh KH, Margetts PJ: Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs. 2005, 28: 129-134.

25.

Labat RJ: Fibronectin in malignancy. Semin Cancer Biol. 2002, 12: 187-195. 10.1016/S1044-579X(02)00022-6.CrossRef

26.

Shi Y, Massague J: Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003, 113: 685-700. 10.1016/S0092-8674(03)00432-X.CrossRef

27.

Feng XH, Derynck R: Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol. 2005, 21: 659-693. 10.1146/annurev.cellbio.21.022404.142018.CrossRef

28.

Tojo M, Hamashima Y, Hanyu A: The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial to-mesenchymal transition by transforming growth factor-β. Cancer Sci. 2005, 96: 791-800. 10.1111/j.1349-7006.2005.00103.x.CrossRef

29.

Nomura H, Nishimori H, Yasoshima T: A novel experimental mouse model of peritoneal dissemination of human gastric cancer cells: analysis of the mechanism of peritoneal dissemination using cDNA microarray. Jpn J Cancer Res. 2001, 92: 748-754.CrossRef

30.

Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J: Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol. 2001, 12: 2029-2039.

31.

Van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH: The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas. 2006, 32: 396-402. 10.1097/01.mpa.0000220865.80034.2a.CrossRef

32.

Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T: Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res. 2004, 64: 6065-6070. 10.1158/0008-5472.CAN-04-0321.CrossRef

Title: Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis
Authors: Zhi-Dong Lv
Di Na
Fu-Nan Liu
Zong-Min Du
Zhe Sun
Zhen Li
Xiao-Yang Ma
Zhen-Ning Wang
Hui-Mian Xu
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-29-139

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives

Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: Phase I trial

Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells

The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients

RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells

Ultrastaging of lymph node in uterine cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer